Who
Arthur Tzianabos
Director
Company insider
Files Form 4 as: President & CEO, Q32 Bio; Interim Executive Chair, Stoke Therapeutics; Director, Akouos; Director, Dnib Unwind; President and CSO, Tempest Therapeutics.
In numbers
- Trades disclosed
- 86
- Buys
- 3
- Sells
- 16
- Bought
- $22K
- Sold
- $3.9M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 10 Sep 2013
- Last trade
- 12 Jun 2026
- Last filed
- 21 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,810 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —9,810 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,786 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,786 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Code M | $33K3,955 at $8.33 | filing |
| 10 Mar 2026filed 12 Mar 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Sold | $174K4,355 at $40.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,955 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,955 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Code M | $33K3,955 at $8.33 | filing |
| 10 Mar 2026filed 12 Mar 2026 | STOK Stoke TherapeuticsBiotechnology | SEC FORM 4 Sold | $174K4,355 at $40.00 | filing |
| 23 Oct 2025filed 27 Oct 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —53,521 at $0.00 | filing |
| 20 Mar 2025filed 20 Mar 2025 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —122,651 at $0.00 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —25,674 at $0.00 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —25,674 at $0.00 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —12,767 at $0.00 | filing |
| 24 Feb 2025filed 27 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —12,767 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | STOK Stoke Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,639 at $0.00 | filing |
| 25 Mar 2024filed 14 Aug 2024 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —1,095 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.